Biomerica (NASDAQ: BMRA) reported a 27% year-on-year improvement in its fourth-quarter net loss to approximately $1.1 million for the fiscal year ended May 31, 2026. The Irvine-based biomedical technology company saw Q4 net sales rise 17% to $875,000, driven by higher contract manufacturing and inFoods revenues.

The company’s quarterly losses per share improved to $(0.38), a significant reduction from the $(0.69) per share loss recorded in the same period last year. This represents a 44.93% improvement in per-share performance, aligning with the broader trend of narrowing absolute losses as revenue grew 16.82% from $749,000 in the prior year quarter.

For the full fiscal year 2026, Biomerica’s net loss improved 24% to $3.8 million from $5.0 million in FY25. This improvement was primarily attributed to higher other income, including approximately $1.1 million from the Employee Retention Credit and a $335,000 unrealized holding gain on its investment in Diagnosis S.A.

Financial Performance

Full-year revenue declined 15% to $4.50 million from $5.30 million in FY25. The decrease was largely due to lower clinical laboratory sales, reduced over-the-counter sales amid international trade uncertainties, and lower contract manufacturing revenue following the completion of a prior R&D project. These declines were partially offset by increased demand for inFoods IBS.

Gross profit fell to $362,000 from $498,000, with gross margin contracting slightly from 9% to 8%. Total operating expenses remained relatively flat at $5.68 million, an increase of less than 1% year-over-year.

Operational Highlights

Research and development expenses decreased 23% to $788,000 as key programs, including inFoods IBS and hp+detect, transitioned toward commercialization. This reduction was offset by higher selling, general, and administrative expenses related to legal, regulatory fees, and commercialization investments.

Net cash used in operating activities improved 11% to $3.42 million from $3.84 million in the prior year. As of May 31, 2026, the company held $1.3 million in cash and cash equivalents, down from $2.4 million a year earlier.

What the Numbers Show

The improvement in Biomerica’s bottom line was not operational but financial. With an operating loss of $5.30 million against a net loss of $3.80 million, other income contributed approximately $1.5 million to the final result. This indicates that nearly 40% of the reported net loss was offset by non-recurring items, specifically the Employee Retention Credit and investment gains, rather than core business profitability.

Strategic Developments

Subsequent to the fiscal year-end, Biomerica completed a private placement raising $2.23 million through the sale of 1.39 million shares at $1.60 per share. The financing included participation from B. Riley Principal Capital and all board members. The company also engaged B. Riley Securities to evaluate potential strategic opportunities, including partnerships and business combinations.

In business operations, Biomerica secured a $1.75 million Master Services Agreement for contract development and manufacturing. Additionally, the company received its first commercial order for the hp+detect H. pylori test from a major European clinical laboratory chain. For inFoods IBS, 100% of initial valid Medicare claims processed to date were paid at the full CMS rate of $300.

Biomerica, Inc. (NASDAQ: BMRA) has commenced a private placement of 1,393,705 unregistered shares of common stock priced at $1.60 per share. The company entered into definitive agreements with institutional and individual investors for the transaction.

The financing is expected to provide approximately $2.23 million in gross proceeds to Biomerica. The shares were priced at $1.60 at the time the definitive agreements were executed. The transaction structure includes no warrants or discounted securities.

Participation and Structure

Key stakeholders participated in the financing, including B. Riley Principal Capital, certain executives and employees of B. Riley Securities, Inc., Biomerica’s Chief Executive Officer, and all members of the Board of Directors. This participation reflects alignment between outside investors and company leadership.

Following closing, the new shares will represent approximately 30.4% of the pro forma shares outstanding. The total pro forma share count is expected to be 4,588,968.

Strategic Outlook

B. Riley Securities will assist Biomerica in reviewing, evaluating, and negotiating potential acquisitions, mergers, joint ventures, partnerships, spin-offs, and other strategic combinations. The goal is to maximize long-term shareholder value through these potential transactions.

Proceeds are intended to strengthen the balance sheet and fund operations while the Board evaluates potential partnerships and business combinations. Biomerica develops and manufactures diagnostic test systems, primarily focusing on gastrointestinal and inflammatory diseases. The company markets advanced diagnostic and therapeutic products used at the point-of-care and in hospital laboratories.